{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:51:44Z","timestamp":1776408704867,"version":"3.51.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Changzhou '14th Five-Year Plan' Key Disciplines"},{"name":"Changzhou '14th Five-Year Plan' Health Leading Talents Training Project"},{"name":"Key project of Jiangsu Province HealthCommittee"},{"name":"Hospital, Changzhou Medical Center, NanjingMedical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06942-0","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:50:52Z","timestamp":1774396252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors for leukemic transformation in myeloproliferative neoplasms and prognostic factors in secondary acute myeloid leukemia: an exploratory analysis of the SEER database"],"prefix":"10.1007","volume":"105","author":[{"given":"Shuainan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyu","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laibing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyu","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4913-1610","authenticated-orcid":false,"given":"Weiying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"6","key":"6942_CR1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","volume":"129","author":"E Rumi","year":"2017","unstructured":"Rumi E, Cazzola M (2017) Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 129(6):680\u2013692","journal-title":"Blood"},{"issue":"33","key":"6942_CR2","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM et al (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098\u20134103","journal-title":"J Clin Oncol"},{"issue":"2","key":"6942_CR3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0609.2008.01163.x","volume":"82","author":"K Abdulkarim","year":"2009","unstructured":"Abdulkarim K et al (2009) AML transformation in 56 patients with Ph- MPD in two well defined populations. Eur J Haematol 82(2):106\u2013111","journal-title":"Eur J Haematol"},{"issue":"3","key":"6942_CR4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","volume":"85","author":"F Cervantes","year":"1991","unstructured":"Cervantes F et al (1991) Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 85(3):124\u2013127","journal-title":"Acta Haematol"},{"issue":"23","key":"6942_CR5","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T et al (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29(23):3179\u20133184","journal-title":"J Clin Oncol"},{"issue":"9","key":"6942_CR6","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874\u20131881","journal-title":"Leukemia"},{"issue":"4","key":"6942_CR7","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/bloodadvances.2021005335","volume":"6","author":"D Martinez-Cuadron","year":"2022","unstructured":"Martinez-Cuadron D et al (2022) Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv 6(4):1278\u20131295","journal-title":"Blood Adv"},{"issue":"26","key":"6942_CR8","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE et al (2018) CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 36(26):2684\u20132692","journal-title":"J Clin Oncol"},{"issue":"5","key":"6942_CR9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.13218","volume":"102","author":"F Huemer","year":"2019","unstructured":"Huemer F et al (2019) Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and\/or BIM. Eur J Haematol 102(5):437\u2013441","journal-title":"Eur J Haematol"},{"issue":"5","key":"6942_CR10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00277-021-04465-4","volume":"100","author":"M Heuser","year":"2021","unstructured":"Heuser M et al (2021) Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol 100(5):1181\u20131194","journal-title":"Ann Hematol"},{"key":"6942_CR11","doi-asserted-by":"crossref","first-page":"1400461","DOI":"10.3389\/fonc.2024.1400461","volume":"14","author":"G Marconi","year":"2024","unstructured":"Marconi G et al (2024) Novel insights and therapeutic approaches in secondary AML. Front Oncol 14:1400461","journal-title":"Front Oncol"},{"issue":"12","key":"6942_CR12","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/ijc.35125","volume":"155","author":"X Dou","year":"2024","unstructured":"Dou X et al (2024) Genomic mutation patterns and prognostic value in de novo and secondary acute myeloid leukemia: A multicenter study from China. Int J Cancer 155(12):2253\u20132264","journal-title":"Int J Cancer"},{"issue":"22","key":"6942_CR13","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood.2024028000","volume":"145","author":"N Polverelli","year":"2025","unstructured":"Polverelli N et al (2025) Role of allo-HCT in nonclassical MPNs and MDS\/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. Blood 145(22):2561\u20132573","journal-title":"Blood"},{"issue":"9","key":"6942_CR14","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.bbmt.2019.05.038","volume":"25","author":"C Nilsson","year":"2019","unstructured":"Nilsson C et al (2019) Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting. Biol Blood Marrow Transpl 25(9):1770\u20131778","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"6942_CR15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A et al (2018) Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia 32(5):1200\u20131210","journal-title":"Leukemia"},{"issue":"7","key":"6942_CR16","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A et al (2018) GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 32(7):1631\u20131642","journal-title":"Leukemia"},{"issue":"13","key":"6942_CR17","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895\u20132901","journal-title":"Blood"},{"issue":"4","key":"6942_CR18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P et al (2018) MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J Clin Oncol 36(4):310\u2013318","journal-title":"J Clin Oncol"},{"issue":"1","key":"6942_CR19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.27136","volume":"99","author":"GG Loscocco","year":"2024","unstructured":"Loscocco GG et al (2024) The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70\/plus\/plus v2.0) for primary myelofibrosis. Am J Hematol 99(1):68\u201378","journal-title":"Am J Hematol"},{"issue":"12","key":"6942_CR20","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","volume":"4","author":"T Karantanos","year":"2020","unstructured":"Karantanos T et al (2020) Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv 4(12):2567\u20132576","journal-title":"Blood Adv"},{"issue":"5","key":"6942_CR21","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.3390\/ijms22052595","volume":"22","author":"T Karantanos","year":"2021","unstructured":"Karantanos T et al (2021) Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology. Int J Mol Sci 22(5):2595","journal-title":"Int J Mol Sci"},{"issue":"10","key":"6942_CR22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41408-018-0128-x","volume":"8","author":"D Barraco","year":"2018","unstructured":"Barraco D et al (2018) Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J 8(10):89","journal-title":"Blood Cancer J"},{"issue":"7","key":"6942_CR23","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","volume":"95","author":"BL Stein","year":"2010","unstructured":"Stein BL et al (2010) Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 95(7):1090\u20131097","journal-title":"Haematologica"},{"issue":"12","key":"6942_CR24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/CM9.0000000000003106","volume":"137","author":"J Chen","year":"2024","unstructured":"Chen J et al (2024) Sex-specific impact on disease outcome and the mutational landscape in essential thrombocythemia: A retrospective cohort study. Chin Med J (Engl) 137(12):1495\u20131497","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"6942_CR25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3324\/haematol.2016.149559","volume":"102","author":"HL Geyer","year":"2017","unstructured":"Geyer HL et al (2017) Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica 102(1):85\u201393","journal-title":"Haematologica"},{"issue":"11","key":"6942_CR26","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ajh.24882","volume":"92","author":"A Tefferi","year":"2017","unstructured":"Tefferi A et al (2017) Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. Am J Hematol 92(11):1193\u20131197","journal-title":"Am J Hematol"},{"issue":"4","key":"6942_CR27","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N et al (2019) 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clin Proc 94(4):599\u2013610","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"6942_CR28","doi-asserted-by":"crossref","first-page":"140","DOI":"10.5581\/1516-8484.20120034","volume":"34","author":"RI Bittencourt","year":"2012","unstructured":"Bittencourt RI et al (2012) Philadelphia-negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter 34(2):140\u2013149","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"12","key":"6942_CR29","doi-asserted-by":"crossref","first-page":"e70056","DOI":"10.1002\/hem3.70056","volume":"8","author":"S Koschmieder","year":"2024","unstructured":"Koschmieder S (2024) Novel approaches in myelofibrosis. Hemasphere 8(12):e70056","journal-title":"Hemasphere"},{"issue":"3","key":"6942_CR30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/era.11.10","volume":"11","author":"JL Spivak","year":"2011","unstructured":"Spivak JL, Hasselbalch H (2011) Hydroxycarbamide: a user\u2019s guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther 11(3):403\u2013414","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"6942_CR31","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057\u20131069","journal-title":"Leukemia"},{"issue":"12","key":"6942_CR32","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","volume":"95","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Barbui T (2020) Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 95(12):1599\u20131613","journal-title":"Am J Hematol"},{"issue":"4","key":"6942_CR33","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3324\/haematol.2018.206151","volume":"104","author":"DP McLornan","year":"2019","unstructured":"McLornan DP et al (2019) State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica 104(4):659\u2013668","journal-title":"Haematologica"},{"key":"6942_CR34","doi-asserted-by":"crossref","unstructured":"Spivak JL (2024) Myeloproliferative Neoplasms: Challenging Dogma. J Clin Med, 13(22)","DOI":"10.3390\/jcm13226957"},{"issue":"4","key":"6942_CR35","doi-asserted-by":"crossref","first-page":"424","DOI":"10.6004\/jnccn.2015.0058","volume":"13","author":"BL Stein","year":"2015","unstructured":"Stein BL et al (2015) Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw 13(4):424\u2013434","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"6942_CR36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-025-01235-7","volume":"15","author":"J Thiele","year":"2025","unstructured":"Thiele J et al (2025) Evolution of WHO diagnostic criteria in Classical Myeloproliferative Neoplasms compared with the International Consensus Classification. Blood Cancer J 15(1):31","journal-title":"Blood Cancer J"},{"issue":"5","key":"6942_CR37","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937\u2013951","journal-title":"Blood"},{"issue":"10","key":"6942_CR38","first-page":"798","volume":"41","author":"ZX Shi","year":"2020","unstructured":"Shi ZX et al (2020) [Pathological characteristics of megakaryocytes in myeloproliferative neoplasms and their correlation with driver gene mutations]. Zhonghua Xue Ye Xue Za Zhi 41(10):798\u2013805","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"6942_CR39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jmoldx.2024.10.003","volume":"27","author":"AB Stone","year":"2025","unstructured":"Stone AB et al (2025) Analysis of Molecular Testing for Suspected Myeloproliferative Neoplasm at a Hybrid Community-Academic Health System. J Mol Diagn 27(1):42\u201353","journal-title":"J Mol Diagn"},{"issue":"1","key":"6942_CR40","doi-asserted-by":"crossref","first-page":"9993","DOI":"10.1038\/s41467-024-54444-2","volume":"15","author":"S Li","year":"2024","unstructured":"Li S et al (2024) An umbrella review of socioeconomic status and cancer. Nat Commun 15(1):9993","journal-title":"Nat Commun"},{"issue":"10","key":"6942_CR41","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/s41416-022-01720-x","volume":"126","author":"A Exarchakou","year":"2022","unstructured":"Exarchakou A et al (2022) Socio-economic inequalities in cancer survival: how do they translate into Number of Life-Years Lost? Br J Cancer 126(10):1490\u20131498","journal-title":"Br J Cancer"},{"issue":"2","key":"6942_CR42","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.beha.2019.05.005","volume":"32","author":"JE Maakaron","year":"2019","unstructured":"Maakaron JE, Mims AS (2019) Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail. Best Pract Res Clin Haematol 32(2):127\u2013133","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"6942_CR43","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE et al (2021) CPX-351 versus 7\u2009+\u20093 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 8(7):e481\u2013e491","journal-title":"Lancet Haematol"},{"issue":"7","key":"6942_CR44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD et al (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"9","key":"6942_CR45","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/fon.11.81","volume":"7","author":"A Ostojic","year":"2011","unstructured":"Ostojic A, Vrhovac R, Verstovsek S (2011) Ruxolitinib: a new JAK1\/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncol 7(9):1035\u20131043","journal-title":"Future Oncol"},{"issue":"5","key":"6942_CR46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s11899-023-00702-x","volume":"18","author":"A Duminuco","year":"2023","unstructured":"Duminuco A et al (2023) A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases. Curr Hematol Malig Rep 18(5):176\u2013189","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06942-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:43Z","timestamp":1776405583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06942-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6942"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06942-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is based on publicly available de-identified SEER data, does not involve human subjects, animals, or biological specimens, meets the criteria for ethical exemption, and has been granted exemption approval by the Institutional Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study uses de-identified, publicly available data from the SEER database; informed consent is not required per ethical guidelines for retrospective studies using anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"No materials from external sources were used, so no permission was required","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"This study is not a clinical trial, so no trial registration was required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"204"}}